Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,224.82 +2.14 (+0.04%) Dow
39,506.68 -6.16 (-0.02%) Nasdaq
16,391.59 +50.72 (+0.31%) Bitcoin USD
62,979.42 +1,502.51 (+2.44%) CMC Crypto 200
1,297.77 +37.57 (+2.98%)
Ikena Oncology, Inc. (IKNA)
| Previous close | 1.2900 |
| Open | 1.3200 |
| Bid | 1.3200 x 100 |
| Ask | 1.3300 x 100 |
| Day's range | 1.3199 - 1.3900 |
| 52-week range | 1.0200 - 7.3800 |
| Volume | |
| Avg. volume | 398,072 |
| Market cap | 64.077M |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event. Details are as follows: Date: Tuesday, April 16, 2024Time: 2:00 p.m. ETWebcast
- GlobeNewswire
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalation study currently recruiting targeted patients Closed 2023 in a strong financial position with $175M; runway into 2H 2026 BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”)
- GlobeNewswire
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference, taking place March 4-6, 2024, in Boston, MA. The Company will also be holding one-on-one investor meetings at the conference. Details on the panel can be found below: Ikena Panelist:
